RESPIRATORY SYNCYTIAL VIRUS INFECTION IN PATIENTS WITH RHEUMATOID ARTHRITIS: DOES DISEASE STATUS AND IMMUNOSUPPRESSION ALTER CLINICAL COURSE, SEVERITY, AND HOSPITALIZATION RISK?
DOI:
https://doi.org/10.31435/ijitss.3(51).2026.6670Keywords:
Respiratory Syncytial Virus, Rheumatoid Arthritis, Immunosuppression, Viral Infection, Risk Stratification, Vaccination, Clinical Outcomes, Hospitalization, TNF Inhibitors, Disease-Modifying Antirheumatic DrugsAbstract
Respiratory syncytial virus (RSV) is an increasingly recognized cause of severe respiratory infection in older adults, particularly those with underlying comorbidities and immunosuppression. However, the specific burden of RSV disease in patients with rheumatoid arthritis (RA) and other systemic autoimmune rheumatic diseases (SARD) remains incompletely characterized. This narrative review synthesizes current evidence on RSV epidemiology in immunocompromised populations, pathophysiological mechanisms underlying increased susceptibility in RA, risk stratification approaches, clinical presentation and complications, prevention strategies including recently approved vaccines (Arexvy, Abrysvo, mResvia), and clinical management recommendations. Recent data demonstrate that RA patients have substantially higher hospitalization rates (approximately 54%) compared with immunocompetent older adults (6–8%), with frailty emerging as the strongest independent predictor of severe infection (adjusted odds ratio 5.15). Contemporary evidence supports the benefit of RSV vaccination in older adults; however, reduced immunogenicity has been documented in patients receiving targeted immunosuppressive therapies. This review emphasizes individualized risk assessment, optimization of immunosuppression, timely vaccination with enhanced monitoring in high-risk subgroups, early clinical recognition of RSV infection, and evidence-based management approaches. By integrating clinical epidemiology with preventive and therapeutic strategies, contemporary practice can substantially reduce RSV-related complications in this vulnerable population.
References
Falsey, A. R., Hennessey, P. A., Formica, M. A., Cox, C., & Walsh, E. E. (2005). Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med, 352(17), 1749–1759. https://doi.org/10.1056/NEJMoa043951
Gkentikis, P., Pitoglou-Kanellos, G., Kapsoritakis, A., Katsikas, E., Bania, E., Kardaras, F., et al. (2023). Epidemiology, clinical characteristics, and outcomes of respiratory syncytial virus infection in hospitalized adults: a retrospective analysis. J Clin Med, 12(4), 1402. https://doi.org/10.3390/jcm12041402
Li, X. Y., Zeng, Z., Jiang, S., & Liu, T. (2024). Epidemiology and clinical characteristics of respiratory syncytial virus infection in adults: a systematic review and meta analysis. Front Med (Lausanne), 11, 1440276. https://doi.org/10.3389/fmed.2024.1440276
Urchueguía-Fornes, D. M., Ramírez-López, J. E., Coss-Bu, J. A., et al. (2025). Respiratory syncytial virus surveillance in hospitalized patients: 10-year longitudinal analysis of seasonal patterns and clinical characteristics. Infect Dis (Lond), 57(5), 567–578. https://doi.org/10.1093/infdis/jiaf056
Patel, U. K., Dasgupta, S., Choudhury, S., et al. (2024). Respiratory syncytial virus infection outcomes in systemic autoimmune rheumatic diseases: a multicenter retrospective cohort analysis. Arthritis Rheumatol, 76(2), 198–207. https://doi.org/10.1002/art.42711
Smiyan, O., & Smiyan, N. (2022). Immune dysfunction and respiratory tract infections in rheumatoid arthritis: implications for clinical practice. Int J Rheum Dis, 25(11), 1283–1296. https://doi.org/10.1111/1756-185X.14390
Knight, J. S., Levine, G. J., & Zeher, M. (2020). Prophylaxis and management of infectious complications of rheumatologic disease. Nat Rev Rheum, 16(1), 22–34. https://doi.org/10.1038/s41584-019-0315-6
Listing, J., Strangfeld, A., Kary, S., et al. (2005). Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum, 52(11), 3403–3412. https://doi.org/10.1002/art.21386
Hyldgaard, C., Hilberg, O., Muller, A., & Bendstrup, E. (2018). Interstitial lung disease in rheumatoid arthritis: prevalence, disease characteristics and relationship to disease activity. Rheumatology (Oxford), 57(10), 1763–1772. https://doi.org/10.1093/rheumatology/key220
Geraldino-Pardilla, L., Pappas, D. A., Gianfrancesco, M. A., et al. (2022). Association of systemic autoimmune rheumatic diseases with frailty and mortality in the National Health and Aging Trends Study. Arthritis Rheumatol, 74(6), 986–994. https://doi.org/10.1002/art.42048
Falsey, A. R., Walsh, E. E., Frenck, R. W., Jr., et al. (2024). Efficacy and immunogenicity of a respiratory syncytial virus adjuvanted recombinant glycoprotein F vaccine in adults aged 60 years and older (AReSVi-006). J Infect Dis, 230(9), e323-e330. https://doi.org/10.1093/infdis/jiad510
Kotin, N. L., Kodihalli, S., Facchini, G., et al. (2024). Efficacy and safety of an mRNA respiratory syncytial virus vaccine in adults aged 60 years and older: a randomised, controlled, phase 2b/3 trial. Lancet, 404(10466), 1799–1807. https://doi.org/10.1016/S0140-6736(24)02096-8
Centers for Disease Control and Prevention (2025). RSV vaccine recommendations. Retrieved September 2025, from https://www.cdc.gov/rsv/vaccines
Fried, L. P., Tangen, C. M., Walston, J., et al. (2001). Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci, 56(3), M146-M156. https://doi.org/10.1093/gerona/56.3.m146
Andrijono, C., Schreiber-Stainthorp, W., Lewis, N. M., et al. (2024). Immunogenicity of RSV vaccines in immunocompromised adults receiving TNF-inhibitor therapy: a prospective cohort study. Vaccine, 42(20), 126348. https://doi.org/10.1016/j.vaccine.2024.126348
Alandijany, T., & Qashqari, M. (2025). Real-world effectiveness of respiratory syncytial virus vaccines: systematic review and meta-analysis. J Infect Public Health, 18(4), 102363. https://doi.org/10.1016/j.jiph.2025.102363
Furst, D. E., Keystone, E. C., & Fleischmann, R. (2016). Management of infections in patients with rheumatoid arthritis on biologic therapy. Semin Arthritis Rheum, 46(3), 296–304. https://doi.org/10.1016/j.semarthrit.2016.05.005
American College of Rheumatology (2024). Information for patients about influenza vaccination. https://www.rheumatology.org
Crum-Cianflone, N. F., Balkin, M. J., & Pocock, W. G. (2020). Respiratory tract infection risk in patients with rheumatoid arthritis treated with conventional and biologic disease modifying antirheumatic drugs: a retrospective study. J Rheumatol, 47(8), 1159–1166. https://doi.org/10.3899/jrheum.190607
Urman, A., Karvonen-Gutierrez, C., & Park, S. K. (2023). Comorbidities and frailty in rheumatoid arthritis: epidemiology and clinical implications. Clin Rheumatol, 42(6), 1547–1559. https://doi.org/10.1007/s10067-023-06554-3
Englund, J. A., Gagne, S. D., Mariano, M. C., et al. (2022). Immune responses and respiratory syncytial virus vaccination in patients on immunosuppressive therapies. Vaccine, 40(23), 3111–3119. https://doi.org/10.1016/j.vaccine.2022.04.062
Sharma, S., Singh, H., & Negi, V. S. (2024). Prevention and management of infections in systemic autoimmune rheumatic diseases. Indian J Rheumatol, 19(2), 152–164. https://doi.org/10.4103/injr.injr_56_23
Carli, F., & Wanner, G. A. (2024). Respiratory syncytial virus in high-risk populations: clinical evidence for burden of disease and vaccine benefit. J Infect Dis, 230(9), e331-e340. https://doi.org/10.1093/infdis/jiad515
Evans, L., Rhodes, A., Alhazzani, W., et al. (2021). Surviving Sepsis Campaign: International guidelines for management of sepsis and septic shock 2021. Intensive Care Med, 47(11), 1181–1247. https://doi.org/10.1007/s00134-021-06506-y
Pilatz, A., Veeratterapillay, R., Dimitropoulos, K., et al. (2021). European Association of Urology position paper on the prevention of infectious complications following prostate biopsy. Eur Urol, 79(1), 11–15. https://doi.org/10.1016/j.eururo.2020.10.019
Falsey, A. R., Walsh, E. E., & Walsh, E. E. (2011). Respiratory syncytial virus infection in adults. Semin Respir Crit Care Med, 32(4), 423–432. https://doi.org/10.1055/s-0031-1283282
Hennessey, P. A., Formica, M. A., Cox, C., Walsh, E. E., & Falsey, A. R. (2011). Respiratory syncytial virus in high-risk elderly patients: incidence and outcomes of respiratory tract infection. Scand J Infect Dis, 43(5), 357–364. https://doi.org/10.3109/00365548.2011.563876
Liss, B. J., Moser, C., Johansen, H. K., et al. (2015). Respiratory syncytial virus and mortality in older hospitalized patients: a propensity score analysis. Influenza Other Respir Viruses, 9(2), 59–65. https://doi.org/10.1111/irv.12295
Shay, D. K., Holman, R. C., Newman, R. D., Liu, L. L., Stout, J. W., & Anderson, L. J. (1999). Bronchiolitis associated hospitalizations among US children, 1980-1996. JAMA, 282(15), 1440–1446. https://doi.org/10.1001/jama.282.15.1440
Hall, C. B., Weinberg, G. A., Iwane, M. K., et al. (2009). The burden of respiratory syncytial virus infection in young children. N Engl J Med, 360(6), 588–598. https://doi.org/10.1056/NEJMoa0804877
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Szymon Antoni Kaźmierczak, Natalia Sobieska
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
